Abstract
Summary Drug availability and dose information for children were assessed by detailed scrutiny of each drug entry in the Data Sheet Compendium 1978 and the British National Formulary 1976-78, and by evaluation of data supplied by the manufacturers from which their dose recommendations were derived. The use of two-thirds of the drugs is limited by disclaimers and inadequate dose information, and for most of the other drugs, the basis on which dose recommendations are made is inappropriate. The limited availability of drugs suggests that more studies on the clinical evaluation of drugs in children are urgently required, and that paediatric clinical pharmacology should be developed as a speciality in Britain.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
